Malaria control is compromised by the development and spread of Plasmodium falciparum resistance to antimalarial drugs, which has caused an increase in malaria related morbidity and mortality. Artemisinin based combination therapy (ACT) has been implemented in almost all malaria endemic areas in an attempt to suppress drug resistance. The ACT artemether-lumefantrine (Coartem®; Novartis) is one ...

Artemether-lumefantrine (AL), dihydroartemisinin-piperaquine (DP), and amodiaquine-sulfadoxine-pyrimethamine (AQ-SP) offer excellent antimalarial efficacy but may select for parasite polymorphisms that decrease drug sensitivity. We evaluated the selection of known polymorphisms in genes encoding putative transporters (pfcrt and pfmdr1) and SP targets (pfdhfr and pfdhps) in parasites that caused...

BACKGROUND Artemether-lumefantrine (AL) was introduced for treatment of uncomplicated malaria in Guinea-Bissau in 2008. Malaria then resurged and recurrent malaria after treatment with AL and stock-outs of AL were common. This study therefore aimed to assess the efficacy of AL and identify an alternative second line antimalarial. Dihydroartemisinin-piperaquine (DP) was chosen as it has been sho...

Artemether-lumefantrine (AL) became the first-line treatment for uncomplicated malaria in Kenya in 2006. Studies have shown AL selects for SNPs in pfcrt and pfmdr1 genes in recurring parasites compared to the baseline infections. The genotypes associated with AL selection are K76 in pfcrt and N86, 184F and D1246 in pfmdr1. To assess the temporal change of these genotypes in western Kenya, 47 pa...

Background High levels Plasmodium falciparum resistance to Chloroquine (CQ) compelled Tanzania to replace CQ with Suphadoxine-pyrimethamine (SP) as first-line antimalarial in 2001 which was however replaced with Artemether Lumefantrine (AL) in 2006. Studies in Malawi have shown sufficient recovery of CQ-sensitivity after its withdrawal warranting re-using CQ in combination with other antimalari...

Safety and efficacy of lumefantrine-artemether (Coartem(R)) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults Malaria Journal 2006, 5:73 doi:10.1186/1475-2875-5-73 Modest Mulenga ([email protected]) Jean-Pierre Van geertruyden ([email protected]) Lawrence Mwananyanda ([email protected]) Victor Chalwe ([email protected]) Filip Moerman (fmoer...

Three thermally and hydrolytically stable silylamide trioxanes have been prepared from the natural trioxane artemisinin in only five simple chemical steps and in at least 56% overall yield. Two of these new chemical entities completely cured malariainfected mice at a single oral dose of only 8 mg/kg combined with 24 mg/kg of mefloquine hydrochloride. The high efficacy of this ACT chemotherapy i...

ognized as responsible for renal disease in tropical areas. Renal manifestations are mainly associated with two parasites: (i) Plasmodium malariae, which usually gives rise to an immune-complex mediated mesangiocapillary glomerulonephritis (GN) several weeks after the onset of symptoms; and (ii) Plasmodium falciparum, which can cause different types of renal alterations, ranging from asymptomat...